Group 1 - Xuan Bamboo Biotech-B (02575) has seen its stock price increase by nearly 70% since its listing, with a recent rise of over 9% to HKD 49.28, and a trading volume of HKD 12.6681 million [1] - On October 22, 2025, Xuan Bamboo Biotech-B announced the presentation of mid-analysis results from the clinical III phase (BRIGHT-3) study on the combination of palbociclib with letrozole or anastrozole for HR+/HER2- advanced breast cancer at the 2025 European Society for Medical Oncology (ESMO) [1] - The China National Medical Products Administration accepted the new drug application for palbociclib combined with aromatase inhibitors (AI) for HR+/HER2- advanced breast cancer on May 14, 2025, based on the mid-term data from the BRIGHT-3 study [1] Group 2 - Palbociclib (brand name: Xuan Yue Ning) is a novel CDK2/4/6 inhibitor with a unique multi-target synergistic mechanism, effectively inhibiting tumor cell proliferation and significantly reducing the hematological toxicity commonly associated with traditional CDK4/6 inhibitors [2] - On May 13, 2025, palbociclib was approved by the China National Medical Products Administration for use in combination with fulvestrant for patients who have progressed after prior endocrine therapy, and as a monotherapy for patients who have progressed after receiving two or more endocrine therapies and one chemotherapy, making it the first and only CDK4/6 inhibitor approved for monotherapy indications in China [2]
港股异动 | 轩竹生物-B(02575)再涨超9% 吡洛西利治疗乳腺癌相关临床数据于2025年ESMO公布